EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

A multicenter prospective clinical trial reveals cell-free DNA methylation markers for early esophageal cancer

Ruixiang Zhang, Yongzhan Nie, Xiaobing Chen, Tao Jiang, Jinhai Wang, Yuhui Peng, Guangpeng Zhou, Yong Li, Lina Zhao, Beibei Chen, Yunfeng Ni, Yan Cheng und 14 weitere

Journal of Clinical Investigation · 15.04.2025 · 135 (8)

DOI: 10.1172/jci186816 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 25.02.2025. Verfasst von Ruixiang Zhang und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, DNA Methylation, Biomarkers, Tumor, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Current methods for detecting esophageal cancer (EC) are generally invasive or exhibit limited sensitivity and specificity, especially for the identification of early-stage tumors. METHODS We identified potential methylated DNA markers (MDMs) from multiple genomic regions in a discovery cohort, and a diagnostic model was developed and verified in a model-verification cohort of 297 participants. The accuracy of the MDM panel was validated in a multicenter, prospective cohort ( n = 1,429). The clinical performance of identified MDMs were compared with current tumor-associated protein markers. RESULTS From 31 significant differentially methylated EC-associated regions identified in the marker discovery, we trained and validated a 3-MDM diagnostic model that could discriminate among patients with EC and volunteers without EC in a multicenter clinical prospective cohort with a sensitivity of 85.5% and a specificity of 95.3%. This panel showed higher sensitivity in diagnosing early-stage tumors, with sensitivities of 56% for stage 0 and 77% for stage I, compared with the performance of current biochemical markers. In population with high risk for EC, the sensitivity and specificity were 85.68% and 93.61%, respectively. CONCLUSION The assessment of tumor-associated methylation status in blood samples can facilitate noninvasive and reliable diagnosis of early-stage EC, which warrants further development to expand screening and reduce mortality rates. TRIAL REGISTRATION ChiCTR2400083525. FUNDING Science and technology funds of Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park. Project number: Z201100005420007.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsDNA MethylationBiomarkers, TumorCell-Free Nucleic AcidsHumansFemaleMaleMiddle AgedProspective StudiesAgedEarly Detection of CancerAdult

Stichwörter der Autor:innen

CancerClinical trialsMolecular diagnosisOncology

Substanzen

Biomarkers, TumorCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China.
  • Department of Thoracic Surgery, Tangdu Hospital, The Air Force Military Medical University, Xi'an, Shaanxi, China.
  • Department of Gastroenterology, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.

Zitieren

APA

Zhang, R., Nie, Y., Chen, X., Jiang, T., Wang, J., Peng, Y., Zhou, G., Li, Y., Zhao, L., Chen, B., Ni, Y., Cheng, Y., Xu, Y., Zhu, Z., Gao, X., Wu, Z., Li, T., Zhao, J., Liu, C., …, & Li, Y. (2025). A multicenter prospective clinical trial reveals cell-free DNA methylation markers for early esophageal cancer. Journal of Clinical Investigation, 135(8). https://doi.org/10.1172/jci186816

Vancouver

Zhang R, Nie Y, Chen X, Jiang T, Wang J, Peng Y, et al. A multicenter prospective clinical trial reveals cell-free DNA methylation markers for early esophageal cancer. Journal of Clinical Investigation. 2025;135(8). doi:10.1172/jci186816

BibTeX
@article{Zhang2025,
  author = {Zhang, Ruixiang and Nie, Yongzhan and Chen, Xiaobing and Jiang, Tao and Wang, Jinhai and Peng, Yuhui and Zhou, Guangpeng and Li, Yong and Zhao, Lina and Chen, Beibei and Ni, Yunfeng and Cheng, Yan and Xu, Yiwei and Zhu, Zhenyu and Gao, Xianchun and Wu, Zhen and Li, Tianbao and Zhao, Jie and Liu, Cantong and Zhao, Gang and Chen, Jiakuan and Zhao, Jing and Ji, Gang and Han, Xiaoliang and He, Jie and Li, Yin},
  title = {A multicenter prospective clinical trial reveals cell-free DNA methylation markers for early esophageal cancer},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {8},
  doi = {10.1172/jci186816}
}
Kostenlos starten →